ClinicalTrials.gg
Active, not recruitingNCT04993638Updated Aug 28, 2024

Post Market Clinical Follow-up of Dual-mobility Acetabular Cup EUROSCUP MOBILE

An observational study in Hip Arthropathy, Hip Osteoarthritis and Hip Arthritis, sponsored by EUROS. Active, not recruiting at 3 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-08-28.

Sponsored by EUROS · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
147
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Osteoarthritis, Hip with a site in France — 10 open to participants now, 16 under way, none of them phase 3. Osteoarthritis, Hip · France.

Enrollment
14th of 17
147 · median 250
Started
2021
with 6 others
Observational
17 of 38
6 open now
Primary completion
2034-06
later than 13 of 15 live
Registered
23rd of 38
by date
Lead sponsor
3 of 38
EUROS

Among the 38 studies in Osteoarthritis, Hip with a site in France, this one is the 14th largest by enrollment of the 17 observational ones that give a count, is one of 7 that started in 2021, is one of 17 observational ones, reaches primary completion later than 13 of the 15 other live ones, and was the 23rd registered.

Osteoarthritis, Hip

642 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.

Browse Osteoarthritis, Hip studies →

Open to participants now

10 of the 38 studies in Osteoarthritis, Hip with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 86 Osteoarthritis, Hip studies recruiting now, 53 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Osteoarthritis, Hip with a site in France, or all of them as a file.
02

Study summary

EUROSCUP MOBILE is intended for use in primary and revision total hip replacement surgery.

Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components.

As part of post market vigilance, EUROS will collect data on EUROSCUP MOBILE performances and safety

Read the detailed description

Post market observational study. This study is retropective and prospective, non comparative.

03

Conditions studied

  • Hip Arthropathy
  • Hip Osteoarthritis
  • Hip Arthritis
  • Hip Fractures
  • Hip Necrosis
  • Hip Dysplasia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient who fulfill the criteria of eligilibilty according to the instructions for use of EUROSCUP MOBILE

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who received EUROSCUP MOBILE.
  • Patient informed of its participation to the study
  • Patient aged between 18 and 80 years old (\<80).

Exclusion criteria

Exclusion Criteria:

  • Patient presenting a to EUROSCUP MOBILE implantation.
  • Patient who refused to participate to the study
  • Vulnerable subjects
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
147 participants (actual)
Patient registry
No

Groups and cohorts

  • EUROSCUP MOBILE cementless

    107 who received cementless version of EUROSCUP MOBILE

    Device: hip arthroplasty

  • EUROSCUP MOBILE cemented

    40 who received cemented version of EUROSCUP MOBILE

    Device: hip arthroplasty

Interventions

  • Devicehip arthroplasty

    Hip prosthesis surgery

06

What researchers measure

Primary outcomes

  1. Safety of EUROSCUP MOBILE

    Collect the safety of the device trought complications occurence rate

    Time frame: 1 year

Secondary outcomes

  1. Radiological performances of EUROSCUP MOBILE

    Collect the performances of the device trought radiological evaluation

    Time frame: 1 year

  2. Clinical performances of EUROSCUP MOBILE

    Collect the performances of the device trought clinical scores

    Time frame: 1 year

  3. Survival of EUROSCUP MOBILE

    Assess the survival rate of the device

    Time frame: 10 year

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jun 2034, 156 months after the start.

Of 81 observational studies under Osteoarthritis, Hip, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 113. This study's planned 156 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2021
First posted
Aug 6, 2021
StartActual
Jun 1, 2021
Primary completionEst.
Jun 1, 2034
CompletionEst.
Jun 2034
Last update
Aug 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04993638
Lead sponsor
EUROS
Responsible party
Sponsor
First posted
Aug 6, 2021
Start date
Jun 1, 2021
Primary completion
Jun 1, 2034 (estimated)
Completion
Jun 2034 (estimated)
Last update
Aug 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion